EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Merck Shuts Down RNAi Research Center in SF, Cutting 50 Jobs

Xconomy San Francisco — 

Merck has decided to close down the RNA interference research facility it obtained through its $1.1 billion acquisition five years ago of San Francisco-based Sirna Therapeutics, the company said late today.

About 50 jobs are being eliminated, while about 10 people are being offered transfers to other Merck (NYSE: MRK) facilities on the East Coast and in Palo Alto, CA, says company spokesman Ian McConnell. The company still plans to utilize the RNAi technology it got via the Sirna acquisition throughout its global R&D operation, he says. Employees in San Francisco, at the facility at 1700 Owens Street in Mission Bay, were told about the shutdown today, McConnell says.

“We continue to invest significantly in the RNA research field, which we believe represents a potentially transformative technology,” McConnell says. “It’s a difficult decision,” he adds, explaining that it was driven by the company’s need to cut costs.

Merck’s acquisition of Sirna raised eyebrows across the industry from the beginning, because of the high price tag, and the early-stage nature of RNAi technology. This technology has electrified scientists for several years, because it offers the potential of hitting biological targets of disease that are currently inaccessible by conventional small-molecules or larger biotech drugs. Merck paid what many considered to be the lavish sum of $1.1 billion to acquire Sirna, one of the first movers in RNAi.

Since then, Merck hasn’t pointed to any RNAi-based drugs that have emerged in its pipeline, and it has publicly emphasized the challenge it has faced finding ways to effectively deliver these drugs in the body. Merck’s decision comes just a few months after fellow pharma giant Roche pulled out of a high-profile RNAi collaboration with Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY). There are no such RNAi-based drugs approved yet by the FDA for sale in the U.S.

Still, McConnell said Merck plans to continue to use the RNAi technology to help screen drug candidates, an effort which Merck vice president Alan Sachs described in an exclusive interview with Xconomy in January 2010. The RNA group at Merck is now headed up by Jeremy Caldwell, McConnell says.

By posting a comment, you agree to our terms and conditions.

  • R. Jones

    RNAi research has always been a waste of money. The only explanation for it comes from The Emperors New Clothes.

    “Once upon a time there lived a vain Emperor whose only worry in life was to dress in elegant clothes.”

    RNAi was new. The researchers who introduced the world to it won the Nobel Prize.

    “We are two very good tailors and after many years of research we have invented an extraordinary method to weave a cloth so light and fine that it looks invisible. As a matter of fact it is invisible to anyone who is too stupid and incompetent to appreciate its quality.”

    It is now official. Every major player has given up on RNAi. But of course Merck claims it isn’t giving up.

    “We continue to invest significantly in the RNA research field, which we believe represents a potentially transformative technology,” McConnell says.

    The Emperor realized that the people were right but could not admit to that. He thought it better to continue the procession under the illusion that anyone who couldn’t see his clothes was either stupid or incompetent. And he stood stiffly on his carriage, while behind him a page held his imaginary mantle.

  • Doc Martin

    The same may well have been said of monoclonal antibodies, as major pharma abandoned R&D efforts in the nineties.
    I recall in the late nineties many dismissing the technology and ridiculing those remaining in it’s development as the previous poster has with RNAi.
    The irony being that those very same companies are among the most successful and sought after companies in the space, having produced blockbuster monoclonal antibody products in the face of all the prior negative sentiment and adversity, which then saw the same major pharma which had earlier abandoned their investment & efforts returning and paying huge premiums for a piece of the action.